Andre van Helvoort Lengert

Mr. Andre van Helvoort Lengert

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Microorganisms
Verified
Journal Article
Open access
PDF file
Guilherme RodriguesGuilherme Rodrigues
Guilherme Rodrigues
LCLeonardo C. F. Cayres
Leonardo C. F. Cayres
FGFernanda P. Gonçalves
Fernanda P. Gonçalves
NTNauyta N. C. Takaoka
Nauyta N. C. Takaoka
ALAndre van Helvoort Lengert
Andre van Helvoort Lengert
Gislane Lelis Vilela de OliveiraGislane Lelis Vilela de Oliveira
Gislane Lelis Vilela de Oliveira
Interactions between gut microbes and disease modifying antirheumatic drugs (DMARDs) have been proposed. The aim of the present study was to evaluate the presence of some specific bacteria in stool samples from Brazilian RA patients receiving DMARDs and correlate these data with diet, clinical parameters, and cytokines. Stool samples were used for gut bacteria evalutation by qPCR. Serum samples were used to quantify IL-4 and IL-10 by flow cytometer. Statistics were performed by Pearson chi-square, Mann–Whitney U test, and Spearman’s correlation. The study included 20 RA patients and 30 healthy controls. There were no significant differences (p > 0.05) in dietary habits between RA patients and controls. Concerning gut bacteria, we observed an increase in relative expression units (REU) of Bacteroides and Prevotella species in stool samples from patients, and a decrease in REU of Clostridium leptum when compared with healthy controls. Positive correlation between Prevotella and rheumatoid factor was detected. The IL-4 and IL-10 concentrations were increased in patients when compared with controls. We concluded that gut bacteria are different between RA patients receiving DMARDs and healthy controls. Further studies are necessary to determine the real role of gut microbes and their metabolities in clinical response to different DMARDs in RA patients.

4 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
IGIzabela Natalia Faria Gomes
Izabela Natalia Faria Gomes
RSRenato J. Silva-Oliveira
Renato J. Silva-Oliveira
LSLuciane Sussuchi da Silva
Luciane Sussuchi da Silva
OMOlga Martinho
Olga Martinho
AEAdriane Evangelista
Adriane Evangelista
RRRui M. Reis
Rui M. Reis
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of cetuximab response are known for HNSCC. Herein, we address the molecular mechanisms underlying cetuximab resistance in an in vitro model. We established a cetuximab resistant model (FaDu), using increased cetuximab concentrations for more than eight months. The resistance and parental cells were evaluated for cell viability and functional assays. Protein expression was analyzed by Western blot and human cell surface panel by lyoplate. The mutational profile and copy number alterations (CNA) were analyzed using whole-exome sequencing (WES) and the NanoString platform. FaDu resistant clones exhibited at least two-fold higher IC50 compared to the parental cell line. WES showed relevant mutations in several cancer-related genes, and the comparative mRNA expression analysis showed 36 differentially expressed genes associated with EGFR tyrosine kinase inhibitors resistance, RAS, MAPK, and mTOR signaling. Importantly, we observed that overexpression of KRAS, RhoA, and CD44 was associated with cetuximab resistance. Protein analysis revealed EGFR phosphorylation inhibition and mTOR increase in resistant cells. Moreover, the resistant cell line demonstrated an aggressive phenotype with a significant increase in adhesion, the number of colonies, and migration rates. Overall, we identified several molecular alterations in the cetuximab resistant cell line that may constitute novel biomarkers of cetuximab response such as mTOR and RhoA overexpression. These findings indicate new strategies to overcome anti-EGFR resistance in HNSCC.

ISIsana Rodrigues Silva
Isana Rodrigues Silva
MRManoela C. A. S. Ramos
Manoela C. A. S. Ramos
LALidia Maria Rebolho Batista Arantes
Lidia Maria Rebolho Batista Arantes
ALAndre van Helvoort Lengert
Andre van Helvoort Lengert
MOMarco A. Oliveira
Marco A. Oliveira
Henrique SilveiraHenrique Silveira
Henrique Silveira
Methylation levels in tumor-suppressor genes and repetitive sequences have previously been used to study the relationship between environmental air pollution and epigenetic changes related to cancer. In this study, we measured the methylation profiles of the promoter regions CDKN2A, MLH1 and APC and the repetitive sequence LINE-1 in 59 workers exposed to the construction environment and in 49 unexposed workers. We also evaluated the micronuclei frequency and levels of trace elements in the blood of all workers. We evaluated of levels of particulate matter and polycyclic aromatic hydrocarbons (PAHs) at the construction site to characterize the environmental exposure. Our findings demonstrated that exposed workers exhibited significantly higher average levels of promoter methylation of CDKN2A, APC, and MLH1 genes and increased hypomethylation of the LINE-1 in comparison to unexposed workers (all p < 0.05). A higher frequency of micronuclei was observed in the exposed group (2 ± 2) compared to the unexposed group (1 ± 1) with p < 0.001. High levels of particulate matter (51–841 μg/m3) and some PAHs were found in samples from the construction environment. In summary, we provide evidence of increased DNA damage and altered DNA methylation of exposed workers, suggesting that genomic approaches to biomonitoring may be an effective way of estimating future cancer risk for construction workers.

29 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Diego Luis RibeiroDiego Luis Ribeiro
Diego Luis Ribeiro
KTKatiuska Tuttis
Katiuska Tuttis
LOLarissa Cristina Bastos de Oliveira
Larissa Cristina Bastos de Oliveira
Juliana Mara SerpeloniJuliana Mara Serpeloni
Juliana Mara Serpeloni
IGIzabela Natalia Faria Gomes
Izabela Natalia Faria Gomes
Lusânia Greggi AntunesLusânia Greggi Antunes
Lusânia Greggi Antunes
Metastatic prostate cancer (mPCa) is resistant to several chemotherapeutic agents. Brachydin A (BrA), a glycosylated flavonoid extracted from Fridericia platyphylla, displays a remarkable antitumoral effect against in vitro mPCa cells cultured as bidimensional (2D) monolayers. Considering that three-dimensional (3D) cell cultures provide a more accurate response to chemotherapeutic agents, this study investigated the antiproliferative/antimetastatic effects of BrA and the molecular mechanisms underlying its action in mPCa spheroids (DU145) in vitro. BrA at 60–100 μM was cytotoxic, altered spheroid morphology/volume, and suppressed cell migration and tumor invasiveness. High-content analysis revealed that BrA (60–100 µM) reduced mitochondrial membrane potential and increased apoptosis and necrosis markers, indicating that it triggered cell death mechanisms. Molecular analysis showed that (i) 24-h treatment with BrA (80–100 µM) increased the protein levels of DNA disruption markers (cleaved-PARP and p-γ-H2AX) as well as decreased the protein levels of anti/pro-apoptotic (BCL-2, BAD, and RIP3K) and cell survival markers (p-AKT1 and p-44/42 MAPK); (ii) 72-h treatment with BrA increased the protein levels of effector caspases (CASP3, CASP7, and CASP8) and inflammation markers (NF-kB and TNF-α). Altogether, our results suggest that PARP-mediated cell death (parthanatos) is a potential mechanism of action. In conclusion, BrA confirms its potential as a candidate drug for preclinical studies against mPCa.

Verified
Journal Article
Open access
PDF file
SPSara Pires
Sara Pires
JBJuliana Sobral de Barros
Juliana Sobral de Barros
SCSilvia Souza da Costa
Silvia Souza da Costa
GCGabriel Bandeira do Carmo
Gabriel Bandeira do Carmo
MSMarília de Oliveira Scliar
Marília de Oliveira Scliar
AKAna Krepischi
Ana Krepischi
Osteosarcoma (OS) is the most prevalent type of bone tumor, but slow progress has been achieved in disentangling the full set of genomic events involved in its initiation and progression. We assessed by NGS the mutational spectrum of 28 primary OSs from Brazilian patients, and identified 445 potentially deleterious SNVs/indels and 1176 copy number alterations (CNAs). TP53 was the most recurrently mutated gene, with an overall rate of ~60%, considering SNVs/indels and CNAs. The most frequent CNAs (~60%) were gains at 1q21.2q21.3, 6p21.1, and 8q13.3q24.22, and losses at 10q26 and 13q14.3q21.1. Seven cases presented CNA patterns reminiscent of complex events (chromothripsis and chromoanasynthesis). Putative RB1 and TP53 germline variants were found in five samples associated with metastasis at diagnosis along with complex genomic patterns of CNAs. PTPRQ, KNL1, ZFHX4, and DMD alterations were prevalent in metastatic or deceased patients, being potentially indicative of poor prognosis. TNFRSF11B, involved in skeletal system development and maintenance, emerged as a candidate for osteosarcomagenesis due to its biological function and a high frequency of copy number gains. A protein–protein network enrichment highlighted biological pathways involved in immunity and bone development. Our findings reinforced the high genomic OS instability and heterogeneity, and led to the identification of novel disrupted genes deserving further evaluation as biomarkers due to their association with poor outcomes.

17 May 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
BSBenjamin J. Steinbeck
Benjamin J. Steinbeck
XGXin D. Gao
Xin D. Gao
AMAmber N. McElroy
Amber N. McElroy
SPSmriti Pandey
Smriti Pandey
JDJordan L. Doman
Jordan L. Doman
Mark OsbornMark Osborn
Mark Osborn